Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19)
Obstet Gynecol. 2023 Nov 14. doi: 10.1097/AOG.0000000000005471. Online ahead of print.ABSTRACTWe conducted a retrospective cohort study of pregnant patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA polymerase chain reaction test or home test who were counseled about taking nirmatrelvir-ritonavir if they were within 5 days of symptom onset. Obstetric and coronavirus disease 2019 (COVID-19) outcomes were compared between patients who did and did not take the medication. Overall, 114 individuals took nirmatrelvir-ritonavir and 323 did not. The cohorts were comparabl...
Source: Obstetrics and Gynecology - November 14, 2023 Category: OBGYN Authors: Bineta B Toure Aisvarya Panakam Sarah L Johns Sharlay K Butler Ruth E Tuomala Khady Diouf Source Type: research
Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19)
Obstet Gynecol. 2023 Nov 14. doi: 10.1097/AOG.0000000000005471. Online ahead of print.ABSTRACTWe conducted a retrospective cohort study of pregnant patients who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection by RNA polymerase chain reaction test or home test who were counseled about taking nirmatrelvir-ritonavir if they were within 5 days of symptom onset. Obstetric and coronavirus disease 2019 (COVID-19) outcomes were compared between patients who did and did not take the medication. Overall, 114 individuals took nirmatrelvir-ritonavir and 323 did not. The cohorts were comparabl...
Source: Obstetrics and Gynecology - November 14, 2023 Category: OBGYN Authors: Bineta B Toure Aisvarya Panakam Sarah L Johns Sharlay K Butler Ruth E Tuomala Khady Diouf Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study
CONCLUSION: Virologic rebound occurred in approximately 1 in 5 people taking N-R, often without symptom rebound, and was associated with shedding of replication-competent virus.PRIMARY FUNDING SOURCE: National Institutes of Health.PMID:37956428 | DOI:10.7326/M23-1756 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Gregory E Edelstein Julie Boucau Rockib Uddin Caitlin Marino May Y Liew Mamadou Barry Manish C Choudhary Rebecca F Gilbert Zahra Reynolds Yijia Li Dessie Tien Shruti Sagar Tammy D Vyas Yumeko Kawano Jeffrey A Sparks Sarah P Hammond Zachary Wallace Jatin M Source Type: research
Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy
Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887. Online ahead of print.NO ABSTRACTPMID:37956432 | DOI:10.7326/M23-2887 (Source: Annals of Internal Medicine)
Source: Annals of Internal Medicine - November 13, 2023 Category: Internal Medicine Authors: Myron S Cohen Elizabeth R Brown Source Type: research
[Translated article] Safety profile of nirmatrelvir-ritonavir: Evidence of adverse events due to DDIs
CONCLUSIONS: Our results show a high number of TDDIs detected were detected between NMV-r and other drugs. This study provides greater knowledge of the drugs involved in such interactions and their potential relationship with the occurrence of adverse events.PMID:37953113 | DOI:10.1016/j.farma.2023.10.009 (Source: Farmacia Hospitalaria)
Source: Farmacia Hospitalaria - November 12, 2023 Category: Drugs & Pharmacology Authors: Álvaro González-Gómez Jose Manuel Caro-Teller Iv án González-Barrios Almudena Castro-Fronti ñán Pedro Pablo Rodr íguez-Quesada Jos é Miguel Ferrari-Piquero Source Type: research
